Blood glucose control may begin to deteriorate within one to two weeks after your final injection, though some glucose-lowering effect may persist for up to four weeks
Most GLP-1 medications do not require dose adjustment in mild to moderate renal or hepatic impairment
A reasonable approach includes: Baseline thyroid function tests (TSH and FT4) before starting GLP-1 therapy Repeat testing at 812 weeks after commencing treatment, particularly if significant weight loss occurs Further monitoring at 6 months , then annually if thyroid function remains stable Additional testing if symptoms of thyroid dysfunction develop After any levothyroxine dose change, NICE NG145 recommends re-checking thyroid function in 68 weeks to assess the adequacy of the adjustment

1:2500, Abcam, Cambridge, UK), Drp-1 (1:2000, Novus Biotechnology, Littleton, CO, USA), Opa-1 (1:2000, Novus Biotechnology, Littleton, CO, USA), LC3A/B (1:2000, Cell Signaling Technology, Danvers, MA, USA), Tom-20 (1:2000, Santa Cruz Biotechnology, Dallas, TX, USA) and MnSOD (1:2000, Millipore, Billerica, MA, USA), Pink-1 (1:1000, BioVision Incorporated, Milpitas, CA, USA), Fis-1 (1:500, Santa Cruz Biotechnology, Dallas, TX, USA) and Parkin (1:500, Cell Signaling Technology, Danvers, MA, USA) for overnight